ASH 2021 Conference Coverage on VuMedi

 

Leukemia
06:56

ASH 2021 Conference Coverage on VuMedi

Acalabrutinib vs. Rituximab + Idelalisib/Bendamustine in R/R CLL: 3-Year Follow-Up of the ASCEND Trial

FEATURING Paolo Ghia
  • 124 views
  • April 20, 2022
08:45

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long-Term OS With Oral Aza in AML in 1st Remission After Intensive Chemo

FEATURING Andrew Wei
  • 710 views
  • February 8, 2022
  • 3
10:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Asciminib vs. Investigator-Selected TKI in Newly Diagnosed Adult Patients With CML-CP: A Multicenter, Open Label, Randomized, Phase III Study

FEATURING Jorge Cortés
  • 114 views
  • January 27, 2022
12:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on ALLG Phase 2 INTERVENE Study: Investigating Novel Triplets to Extend Remission With Venetoclax in Elderly AML

FEATURING Chong Chyn Chua
  • 19 views
  • January 27, 2022
08:50

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Results From the SEQUOIA Study: Zanubrutinib vs. Bendamustine + Rituximab for Treatment-Naïve CLL/SLL

FEATURING Constantine Tam
  • 113 views
  • January 18, 2022
07:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular MRD and Early Relapse in AML

FEATURING Tiong Ing Soo
  • 15 views
  • January 11, 2022
12:07

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenetapopt & Azacitidine in Patients With TP53 Mutant MDS and Oligoblastic AML

FEATURING David Sallman
  • 76 views
  • January 11, 2022
11:06

ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Assessment in CLL

FEATURING Paolo Ghia
  • 385 views
  • January 4, 2022
  • 2
05:49

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-Rearranged and NPM1-Mutant Acute Leukemia: Ph 1 First-in-Human Study of SNDX-5613

FEATURING Eytan Stein
  • 130 views
  • December 23, 2021
  • 1
08:38

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias and MDS and COVID-19 Infection

FEATURING Pinkal Desai
  • 277 views
  • December 23, 2021
  • 2
09:55

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Therapy in AML

FEATURING Pinkal Desai
  • 102 views
  • December 23, 2021
12:29

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

FEATURING Pinkal Desai
  • 518 views
  • December 23, 2021
  • 2
05:46

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy for AML Based on Their Antecedent History of Myeloid Malignancy

FEATURING Akriti Jain
  • 12 views
  • December 22, 2021
21:44

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL

FEATURING Joanna Rhodes
  • 252 views
  • December 22, 2021
11:34

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Novel Advances in AML Therapy

FEATURING Eunice Wang
  • 227 views
  • December 20, 2021
  • 2
17:05

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Therapy of p53 Mutant Hematologic Malignancies

FEATURING Matthew Davids
  • 224 views
  • December 20, 2021
07:41

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Risk Patient Cohort With Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

FEATURING Jake Soumerai
  • 34 views
  • December 16, 2021
24:40

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on MRD in ALL: Standard of Care & Areas for Further Investigation

FEATURING Lori Muffly
  • 454 views
  • December 16, 2021
  • 3
10:28

ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Directed Therapy: A New Frontier in AML

FEATURING Andrew Wei
  • 445 views
  • December 16, 2021
  • 2